Arcutis Biotherapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

ARQT$27.39+4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenues:
Product revenue, net	$81,504	$30,858	$145,350	$52,427
Other revenue	—	—	2,000	28,000
Total revenues	81,504	30,858	147,350	80,427
Operating expenses:
Cost of sales	7,492	3,464	16,322	6,720
Research and development	19,453	19,298	36,996	42,439
Selling, general and administrative	69,170	58,173	133,172	112,967
Total operating expenses	96,115	80,935	186,490	162,126
Loss from operations	(14,611)	(50,077)	(39,140)	(81,699)
Other income (expense):
Other income, net	2,096	5,229	4,826	9,273
Interest expense	(3,029)	(7,484)	(6,011)	(14,964)
Loss before income taxes	(15,544)	(52,332)	(40,325)	(87,390)
Provision for income taxes	342	—	621	324
Net loss	$(15,886)	$(52,332)	$(40,946)	$(87,714)
Other comprehensive income (loss):
Unrealized loss on marketable securities	(95)	(127)	(232)	(243)
Foreign currency translation adjustment	200	(34)	204	(55)
Total other comprehensive income (loss)	105	(161)	(28)	(298)
Comprehensive loss	$(15,781)	$(52,493)	$(40,974)	$(88,012)
Per share information:
Net loss per share, basic and diluted	$(0.13)	$(0.42)	$(0.32)	$(0.75)
Weighted-average shares used in computing net loss per share, basic and diluted	126,997	123,481	126,519	117,265

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.